Revance Therapeutics Inc. (NASDAQ:RVNC) reached a new 52-week low on Wednesday . The stock traded as low as $12.61 and last traded at $12.91, with a volume of 98,708 shares. The stock had previously closed at $12.91.

Several research firms have weighed in on RVNC. Brean Capital restated a “hold” rating on shares of Revance Therapeutics in a research note on Thursday, June 23rd. SunTrust Banks Inc. cut their target price on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, June 14th. Piper Jaffray Cos. restated an “overweight” rating and set a $35.00 target price (down from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Guggenheim restated a “buy” rating and set a $55.00 target price on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, Zacks Investment Research cut Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $40.46.

The stock’s market capitalization is $365.79 million. The company’s 50-day moving average price is $16.35 and its 200 day moving average price is $19.78.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.12. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. On average, equities analysts predict that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current fiscal year.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. EAM Investors LLC acquired a new position in Revance Therapeutics during the fourth quarter worth $3,512,000. Jennison Associates raised its position in Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock worth $2,326,000 after buying an additional 603 shares in the last quarter. Columbus Circle Investors raised its position in Revance Therapeutics by 139.8% in the fourth quarter. Columbus Circle Investors now owns 61,295 shares of the biopharmaceutical company’s stock worth $2,094,000 after buying an additional 35,734 shares in the last quarter. Oxford Asset Management acquired a new position in Revance Therapeutics during the fourth quarter worth $1,993,000. Finally, Russell Frank Co acquired a new position in Revance Therapeutics during the fourth quarter worth $1,384,000.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.